Elvitegravir | Radio Compass News

FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets

15 Jun 2023 //

FDA

Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma

29 Jan 2019 //

PATENT LITIGATION

California reports show drug spending changes as 2 companies sue over disclosure

03 Jan 2019 //

STAT NEWS

China National Drug Administration Approves Gilead`s Genvoya

06 Aug 2018 //

PRESS RELEASE

Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences

07 Feb 2018 //

PATENT LITIGATION

Gilead’s genvoya shows significantly higher rates of virologic suppression

15 Feb 2017 //

PHARMABIZ

The Glaxo-Gilead HIV Battle Could Be Epic

28 Dec 2016 //

SEEKING ALPHA

Gilead asks FDA to Expand Exclusivity for a Key HIV Drug

21 Oct 2016 //

STAT

Gilead Sciences (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) Approved In US

07 Sep 2016 //

FDA

Gilead gains next-gen HIV approval from FDA as it looks to beat back competition

06 Apr 2016 //

FIERCE BIOTECH

Gilead`s latest HIV cocktail wins FDA approval with a blockbuster pedigree

01 Mar 2016 //

FIERCE BIOTECH

EU clears single pill HIV therapy Genvoya

25 Nov 2015 //

PHARMATIMES

NCE Exclusivity Challenges are hot! Hot! HOT! Ferring Lets Loose with the Latest Lawsuit Challenging Denial of NCE Exclusivity for Colon Cleansing Drug

08 Jun 2015 //

FDA LAW BLOG

Gilead`s low-dose, high-impact HIV drug heads to the FDA

09 Apr 2015 //

SAN FRANSISCO BUSINESS TIMES

Gilead Reports Positive Results from Preclinical Study of Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys

27 Feb 2015 //